Buoyed by strategic brand exits and tariff mitigation, Church & Dwight enters 2026 with robust cash flow and a sharpened focus on its 'power brands' like Arm & Hammer and TheraBreath, despite a challenging consumer landscape.
Quantum computing firm IonQ has moved to acquire SkyWater Technology, Skyloom Global, and Seed Innovations, aiming to create a comprehensive, end-to-end platform that controls hardware, networking, and software. This vertical integration strategy targets government and enterprise clients seeking secure, full-stack quantum solutions.
Hitachi, Ltd. announces a ¥100 billion share repurchase and a sweeping leadership reshuffle across its core divisions, sharpening its focus on digital and AI-driven growth. While the move underscores a commitment to shareholder returns and a transformed future, analysts caution that execution risks and a premium valuation loom large.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
A dual shift in U.S. sanctions and Venezuelan oil law is unlocking the country's vast reserves for American companies, marking a potential turning point after decades of nationalization and economic isolation.
Kraft Heinz announces a major corporate split, separating its global sauces division from its North American grocery business, while Berkshire Hathaway begins selling down its significant stake. The moves signal a strategic pivot for the iconic food giant, raising questions about valuation, dividends, and long-term direction in a shifting consumer landscape.
Campbell Soup Company announces the closure of its Hyannis, Massachusetts snacks facility, consolidating Cape Cod and Kettle Brand production. The move signals a significant supply chain realignment as the CPB stock shows mixed performance, raising questions about long-term value and market positioning.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Dover Corporation topped revenue and profit forecasts for the fourth quarter, fueled by robust order growth in climate tech and retail segments. However, shares dipped as management issued a guarded outlook for the coming year, citing input cost pressures and macroeconomic uncertainty.
The parent company of numerous restaurant chains will be removed from the Nasdaq exchange on February 4, transitioning to high-risk over-the-counter trading after failing to meet listing requirements.
Despite a six-month rally fueled by strong quarterly results, analysts point to sluggish long-term sales growth, weak cash flow, and declining returns on capital as reasons for caution, suggesting investors look elsewhere for opportunity.
Under new CEO César Vargas, the family-owned group is breaking into five autonomous business units in a bid to boost agility and market responsiveness, as it eyes growth beyond its €900m turnover.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
